Co-chair HTA Task Force,
European Federation of Pharmaceutical Industries and Associations,
Vice President, GlaxoSmithKline
Born in Rome, Andrea Rappagliosi received a law degree from the University of Rome "La Sapienza" and completed a post-graduate Masters at the Istituto Superiore dei Studi Legislativi (ISLE) from which he obtained a "Legislative Consultant Diploma".
He began his career in the early eighties, first in the Italian Government as a member of staff for the State Undersecretary of the Treasury, then for the Italian Senate focused on drafting of legislative texts, comparative legal studies and public budget analysis.
In 1992, he moved into healthcare and worked for The Ares-Serono Group as Head of the Institutional Affairs Department in charge of the Rome and Brussels offices. From 1995 to 1999, he was Public Affairs Director at Baxter Healthcare, part of the European Public Affairs team. In 1999, he returned to Serono International, today Merck Serono International, as Vice President Health Policy & Market Access Europe.
In April 2009, Andrea joined GlaxoSmithKline as Vice President European Government Affairs & Head of Brussels Office.
- On June 2009, he has been appointed Chair of the Board of EuropaBio, the European Association of Bioindustries.
- On June 2010, he has been appointed co-Chair of the HTA Task Force of EFPIA, the European Association of the R&D pharmaceutical Industry.
- From 2005 to 2008, he has been member of the European Commission High Level Pharmaceutical Forum representing EuropaBio, the European Association for Bioindustry.
- He sits on the Board of the Foundation of the European Platform for Patients Organizations, Science & Industry (EPPOSI).
- He is member of HTAi (the International Society of Health Technology Assessment) and member of its Policy Forum.
- He has been Industry representative at the EMEA/COMP (European Medicines Evaluation Agency/ Committee for Orphan Medicinal Products) Working Group with Interested Parties in the first two terms 2000 to 2005.
- He is member of the British Institute of International and Comparative Law and is a member of the Editorial Board of the Journal of Commercial Biotechnology.